While neoadjuvant immunochemotherapy has improved outcomes of resectable nonsmall cell lung cancer (NSCLC), treatment-induced tissue changes can increase surgical complexity. This study aimed to identify preoperative predictors of technically challenging surgery following neoadjuvant immunochemotherapy. This multicenter retrospective analysis included 114 patients who underwent surgery after neoadjuvant nivolumab plus platinum-based chemotherapy at 29 institutions between March 2023 and July 2024. Challenging surgery was defined as one requiring bronchoplasty, pulmonary artery angioplasty, or pneumonectomy. Logistic regression was used to identify preoperative predictors for surgical complexity. Twenty-one patients (18.4
INTRODUCTION:Antibiotics and proton pump inhibitors (PPIs) have been associated with the reduced efficacy of immune checkpoint inhibitor (ICI) in patients with advanced non-small cell lung cancer (NSCLC). This study assessed the clinical impact of these medications in the neoadjuvant setting. PATIENTS AND METHODS:This multicenter retrospective study was conducted in 29 Japanese institutions. Between March 2023 and July 2024, 131 patients with resectable clinical stage II-III NSCLC who received neoadjuvant chemoimmunotherapy with nivolumab were enrolled. In total, 113 patients who underwent definitive surgery were included in the surgical outcome analysis. We investigated the association between the use of antibiotics and PPIs within 30 days before treatment initiation and clinicopathological factors, including the pathological complete response (pCR) and major pathological response (MPR). RESULTS:Among 113 patients, 5 (4.4%) had received antibiotics and 23 (20.4%) PPIs. Antibiotic and PPI use showed no significant differences in any clinicopathological factors. Antibiotic and PPI use was not significantly associated with the objective response rate (ORR), pCR, or MPR; antibiotic (use/non-use): 80.0%/70.4% (p = 1.000), 40.0%/35.8% (p = 1.000), 60.0%/59.6% (p = 1.000) and PPI (use/non-use): 78.3%/68.9% (p = 0.532), 43.5%/33.3% (p = 0.507), 60.9%/58.9% (p = 1.000). CONCLUSION:Prior use of antibiotics and PPIs was not significantly associated with radiological or pathological response of neoadjuvant ICI in patients with resectable NSCLC. Further studies with larger sample size and longer survival follow-up are needed.
Study Design:Retrospective cohort study. Purpose:To determine whether preoperative trunk and lower limb muscle quality predicts achievement of the minimal clinically important difference (MCID) in the 6-minute walk distance (6MWD) after lumbar spinal stenosis (LSS) surgery. Overview of Literature:LSS commonly causes intermittent claudication and reduced walking ability. Previous studies have suggested that muscle quality affects postoperative recovery, but its association with clinically meaningful improvements in the 6MWD remains unclear. Methods:This retrospective study included 150 patients aged ≥60 years who underwent decompression or fusion surgery for LSS at Okayama Rosai Hospital between April 2021 and April 2023. Preoperative assessments included demographic and surgical factors, Zurich Claudication Questionnaire (ZCQ) scores, visual analog scale scores, the 6MWD, and computed tomography-based muscle quality. The functional cross-sectional areas of the psoas major, erector spinae (ES), multifidus, gluteus maximus, and gluteus medius were quantified in Hounsfield units. Muscle quality was expressed as the low-attenuation muscle area (LAMA) ratio. Patients were classified according to whether they achieved the MCID (80 m) in the postoperative 6MWD. Logistic regression analyses were used to identify predictors of the achievement of the MCID. Results:Among the 150 patients, 86 (57%) achieved the MCID. Univariate analysis showed that younger age, higher preoperative ZCQ scores, a shorter 6MWD, and lower LAMA ratios of all examined muscles were significantly associated with the achievement of the MCID in postoperative walking ability. In multivariate analysis, younger age (p <0.001), a shorter preoperative 6MWD (p =0.016), and a lower ES LAMA ratio (p <0.001) remained independent predictors. These results indicate that better preoperative ES muscle quality independently contributes to postoperative walking recovery in patients with LSS. Conclusions:Preoperative younger age, shorter 6MWD, and lower ES LAMA ratio independently predicted meaningful postoperative improvement in walking. Enhancing preoperative ES muscle quality is crucial for postoperative walking recovery in patients with LSS.
Venous thromboembolism (VTE) is a serious complication in patients with cancer. In this population, the presence of thrombi is often assessed at cancer diagnosis by measuring D-dimer levels, which have high sensitivity but low specificity for identifying VTE at this clinical time point. However, the usefulness of D-dimer measurement during anticoagulation therapy has not been fully established, despite its widespread use. In this retrospective observational study, we investigated whether D-dimer measurement during anticoagulation therapy in cancer patients could predict overt VTE at follow-up. The study included patients who underwent D-dimer testing and contrast-enhanced computed tomography between 30 and 100 days after initiation of anticoagulation therapy. Eighty-two patients were included: 60 with cancer and 22 without. The diagnostic performance of D-dimer for overt VTE was as follows: sensitivity, 85.7%; specificity, 87.2%; positive predictive value, 78.3%; and negative predictive value, 89.2%. These findings suggest that D-dimer measurement at follow-up has high sensitivity and specificity for overt VTE in cancer patients and may aid in assessing thrombotic status. Clinically, if anticoagulation therapy is continued until D-dimer levels become negative, the absence of overt VTE could be inferred without additional invasive testing.
A CD79B-targeted antibody-drug conjugate, polatuzumab-vedotin has significantly improved outcomes in DLBCL, particularly in the activated B-cell-like (ABC) subtype. This indicates that CD79B expression varies among COO subtypes, although the expression level was not necessarily higher in ABC-DLBCL. Here, we evaluated CD79B protein expression by immunohistochemistry (IHC) in 590 de novo DLBCL cases, observing a CD79B gradient according to COO subtypes, with ABC-DLBCL showing the lowest expression, followed by GCB and dark-zone signature-positive (DZsigpos) cases in ascending order (P < 0.0001). This observation was fully validated in an independent population-based cohort of 272 cases derived from BC Cancer registry. Given that COO classification reflects the stages of normal germinal center (GC) B-cell differentiation, we further explored CD79B expression dynamics during B-cell maturation by performing single-cell proteomic and transcriptomic analyses. Analyses of 2,447 normal GC B-cells demonstrated a progressive decrease in CD79B expression as GC B-cells transitioned toward terminal differentiation. Collectively, our findings reveal a novel COO-dependent gradient of CD79B expression, particularly with lower expression in ABC-DLBCL.
